This article discusses the importance of diagnosis and the management of Brugada Syndrome. Epidemiological and pathophysiological aspects of the syndrome and modern approaches to therapy and genetic analysis will be introduced.

Keywords:brugada syndrome; epidemiology; pathophysiology; recommendations

Brugada syndrome (BS) is defined by ST-segment elevation in right precordial leads (V1 to V3) that as it was reported in early 1953 is unrelated to ischemia, electrolyte disturbances, or obvious structural heart disease. BS was first described as a distinct clinical entity associated with a high risk of sudden cardiac death in 1992 by the Brugada brothers.^1,2 In 1992 it has originally been described as an autosomal-dominant inherited arrhythmic disorder defined by ST elevation with successive negative T wave without structural cardiac abnormalities in the right precordial leads.³ In 1996, in the description of the cellular basis for the J-wave of the ECG by Yan and Antzelevitch, focal point was the importance of ST-segment elevation (accentuated J-wave) and apparent right bundle branch block (RBBB) syndrome, specified by Brugada and Brugada, and named it the “Brugada syndrome” Kobayashi et al. and Miyazaki et al. followed suit that same year.⁴

Epidemiology

As in parts of Asia (eg, the Philippines, Thailand, Japan) it seems to be the most common cause of natural death among men younger than 50years, Brugada syndrome is known as Lai Tai (Thailand), Bangungot (Philippines), and Pokkuri (Japan). In Northeast Thailand, the mortality rate from Lai Tai is approximately 30 cases per 100,000 inhabitants per year.^5,6 Since Brugada syndrome has been identified recently, the predominance of it isn’t enacted well. In a large university hospital on the West Coast of the United States, the prevalence of a Brugada ECG pattern among unselected, mainly white and Hispanic adults was 2 of 1348 patients (0.14%); in both cases, the ECG patterns were type 2. Brugada syndrome is 8-10 times more predominant in men than in women. The penetrance of the mutation appears to be much higher in men than in women, even though that the probability of having a mutated gene does not differ by sex. Brugada syndrome most commonly affects healthy men aged 30-50years, but affected patients aged 0-84years have been reported. Meanwhile the mean age of patients who die suddenly is 41years.⁷

Pathophisiology

Brugada syndrome is a Na channelopathy, which is caused by a variation in the transmembrane ion currents that in conjunction form the cardiac action potential. In 10-30% of cases mutations are discovered in the SCN5A gene (encodes cardiac voltage-gated sodium channel) that reduce the sodium current (INa) available during the phases 0 and 1 of the cardiac action potential. This decrease in INa is believed to affect the right ventricular endocardium differently from the epicardium. It underlies both the Brugada ECG pattern and the clinical manifestations of the Brugada syndrome. The exact mechanisms of the ECG alterations and arrhythmogenesis in Brugada syndrome are contentious since the repolarization-defect theory underlies on the fact that right ventricular epicardial cells display a more conspicuous notch in the action potential than endocardial cells. This is believed to be because of an increased contribution of the transient outward current (Ito) to the action potential waveform in that tissue.⁸ One of the studies that used ajmaline provocation to elicit a type 1 Brugada ECG pattern in 91 patients, found that the repolarization abnormalities were consistent with the depolarization abnormalities and turned out to be secondary to the depolarization changes.⁹

ECG

One true diagnostic Brugada pattern, two others may suggest the disease. Type 1: It is characterised by a prominent coved ST-segment elevation displaying J-point amplitude or ST-segment elevation ≥2mm, followed by a negative T wave. Type 2: It has ≥2mm J-point elevation, ≥1mm ST-segment elevation and a saddleback appearance, followed by a positive or biphasic T-wave. Type 3: It has either a saddleback or coved appearance, but with an ST-segment elevation <1 mm (Figure 1).

Figure 1  Transmembrane action potentials in patients with Brugada syndrome.

Genetic

Thus far, mutations in 11 genes have been associated with the Brugada syndrome. Most of these mutations reduce the cardiac sodium current (INa), the other ones decrease the L-type calcium current (ICaL). The first ones are located in SCN5A, the gene encoding the cardiac sodium channel, its β-subunits SCN1B and SCN3B or in GPD1L and MOG1 which are thought to impair trafficking of the cardiac sodium channel to the cell membrane, mutations decreasing the ICaL are located in CACNA1C, CACNB2b and CACNA2D1 which encode the α1-, β2b-, and α2δ-subunit of the L-type calcium channel. Finally, with the Brugada syndrome were associated both the mutations in KCNE3 which encode MiRP2, a β-subunit of several potassium channels and in KCNJ8 encoding the ATP-sensitive potassium channel. Earlier, during the action potential some currents were activated, for increasing the repolarization of those, these mutations have been suggested.^10,11

ESC recommendations

In 2015 ECS has published new guidelines for the management of patients with ventricular arrhythmias and prevention of sudden cardiac death, in which Brugada Syndrome is mentioned too. Brugada syndrome is diagnosed in patients with ST-segment elevation with type 1 morphology ≥2mm in one or more leads among the right precordial leads V1 and/or V2 positioned in the second, third, or fourth intercostal space, occurring either spontaneously or after provocative drug test with intravenous administration of sodium channel blockers (such as ajmaline, flecainide, procainamide or pilsicainide). ESC recommendations suggest the ICD as the only treatment able to reduce the risk of SCD in Brugada syndrome, thus the appliance can be applyed in patients both with documented VT or VF and in patients presenting with a spontaneous type 1 ECG and a history of syncope¹² (Table 1).

Table 1 Risk stratification and management in Brugada Syndrome by ESC

AHA recommendations

There is no significant difference between the recommendations of ESC and AHA for the BS therapeutic interventions. The only difference that has to be mentioned is that AHA recommentations don't indicate ICD implantation in asymptomatic BS in patients with a drug-induced Type I ECG and based on family history of SCD (Table 2).

Table 2 Expert Consesus Recommendations on Brugada Syndrome Therapeutic Interventions by AHA

On the AHA recommendations In asymptomatic patients, the following findings are considered supportive for the diagnosis of BrS:

1. Attenuation of ST-segment elevation at peak of exercise stress test followed by its appearance during recovery phase. It should be noted, however, that in selected BrS patients, usually SCN5A mutation-positive patients, it has been observed that ST-segment elevation might become more evident during exercise.
2. Presence of first-degree atrioventricular (AV) block and left-axis deviation of the QRS.
3. Presence of atrial fibrillation.
4. Signal-averaged ECG; late potentials.
5. Fragmented QRS.
6. ST-T alternans, spontaneous left bundle branch block. (LBBB) ventricular premature beats (VPB) during prolonged ECG recording.
7. Ventricular effective refractory period (ERP) o200 ms recorded during electrophysiological study (EPS) and HV interval 460ms
8. Absence of structural heart disease including myocardial ischemia.¹³

Quinidine therapy

Quinidine was the most commonly used medication for the prevention of ventricular and atrial arrhythmias as recently as 2 decades ago. Nowadays the use of quinidine is limited because of its side effects and the presence of more safe and effective modern antiarrhythmic drugs. Thus far, in the Brugada syndrome genetic mutations reducing sodium inflow currents are detected in defective myocardial sodium channels which resulted in shorter-than-normal action potentials. Since prominent Ito (transient outward) current in the right ventricular epicardium further shortens the action potentials, Antzelevitch propose that quinidine may exert its favorable effects in Brugada syndrome by inhibiting Ito, and as a result restores electrical homogeneity. Quinidine has effectively been used by Belhassen et al.,¹⁴ as the sole therapy (without ICD back-up) for patients with symptomatic Brugada syndrome, including patients who had spontaneous VF before the initiation of therapy. Recent study shows that none of the 50 patients with symptomatic or asymptomatic Brugada syndrome developed symptomatic ventricular arrhythmias at the same time on quinidine therapy during a follow-up period within from 3months to more than 10years. 600-1500mg/d dosage of quinidine is recommended (In special cases dose can vary from 475 to 2000mg/d). (The effective level of quinidine in serum blood ranges from 1.29 to 5.2mg/L). The effective quinidine serum blood levels ranges from 1.29 to 5.2mg/L. The effectiveness of low dose quinidine (200mg/d) is not proven but Belhassen et al. used it for patients with side effects of quinidine after the administration of standard dosage. Most of the quinidine side effects are dose related.^14,15

The implied risk of a tragic and preventable event - sudden death - in young and, otherwise, healthy individuals because of Brugada Syndrome determines the huge importance of right diagnosis and management of BS by healthcare professionals all over the world.

None.

Author declares there are no conflicts of interest.

None.

1. Osher HL, Wolff L. Electrocardiographic pattern simulating acute myocardial injury. Am J Med Sci. 1953;226(5):541‒545.
2. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20(6):1391‒1396.
3.  Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation. 2002;106(19):2514‒2519.
4. Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J- wave. Circulation. 1996;93(2):372‒379.
5. Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation . 1997;96(8):2595‒2600.
6. Donohue D, Tehrani F, Jamehdor R, et al. The prevalence of Brugada ECG in adult patients in a large university hospital in the western United States. Am Heart Hosp J. 2008;6(1):48‒50.
7.  Antzelevitch C, Brugada P, Brugada J, et al. Brugada syndrome: from cell to bedside. Curr Probl Cardiol. 2005;30(1):9‒54.
8. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more?. Cardiovasc Res. 2005;67(3):367‒378.
9. Postema PG, van Dessel PF, Kors JA, et al. Local depolarization abnormalities are the dominant pathophysiologic mechanism for type 1 electrocardiogram in brugada syndrome a study of electrocardiograms, vectorcardiograms, and body surface potential maps during ajmaline provocation. J Am Coll Cardiol. 2010;55(8):789‒797.
10. Charles Antzelevitch, Eyal Nof. Brugada Syndrome: Recent Advances and Controversies. Curr Cardiol Rep . 2008;10(5):376‒383.
11. Burashnikov E, Pfeiffer R, Barajas-Martinez H, et al. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm. 2010;7(12):1872‒1882.
12. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793‒2867.
13. Silvia G Priori, Arthur A Wilde, Minoru Horie, et al. HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of  Patients with Inherited Primary Arrhythmia Syndromes. Document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm journal . 2013;10(12):1932‒1963.
14. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation . 2004;110(13):1731‒1737.
15.  Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol. 1998;9:513‒516.